Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation

被引:21
作者
Szekerres, T
Haushafer, A
机构
[1] Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost 5H, Gen Hosp Vienna, A-1090 Vienna, Austria
[2] St Polten Hosp, Cent Lab, St Polten, Austria
关键词
cyclosporin; organ transplantation; pharmacogenetics; single nucleoride polymorphism; tacrolimus;
D O I
10.1517/14622416.6.2.163
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Organ transplantation has become an important additional option for patients with organ failure. immunosuppressive drugs showing a very narrow therapeutic window have to be administered. Different transporters and metabolic pathways are responsible for absorption and metabolism of these drugs; for instance, the P-glycoprotein (P-gp) pump regulates the absorption of a drug, and its metabolism is catalyzed by cytochrome P450s (CYPs). As the phenotypes of P-gp or the CYPs are predetermined by their genotypes, genetic testing prior to drug therapy may help to predict the drug doses required. This review describes polymorphisms of the genes coding for P-gp and CYPs, and focuses on the compounds cyclosporin and tacrolimus. it is hoped that this information might help to judge the value of pharmacogenetic testing prior to immunosuppressive therapy in solid organ transplantation.
引用
收藏
页码:163 / 168
页数:6
相关论文
共 25 条
[1]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[2]   Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives [J].
Anglicheau, D ;
Legendre, C ;
Thervet, E .
TRANSPLANTATION, 2004, 78 (03) :311-315
[3]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[4]   Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates [J].
Balram, C ;
Sharma, A ;
Sivathasan, C ;
Lee, EJD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (01) :78-83
[5]   MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients [J].
Bonhomme-Faivre, L ;
Devocelle, A ;
Saliba, F ;
Chatled, S ;
Maccario, J ;
Farinotti, R ;
Picard, V .
TRANSPLANTATION, 2004, 78 (01) :21-25
[6]   Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients [J].
Chowbay, B ;
Cumaraswamy, S ;
Cheung, YB ;
Zhou, QY ;
Lee, EJD .
PHARMACOGENETICS, 2003, 13 (02) :89-95
[7]   Clinical aspects of the MDRI (ABCB1) gene polymorphism [J].
Eichelbaum, M ;
Fromm, MF ;
Schwab, M .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :180-185
[8]  
Fredericks Salim, 2003, Am J Pharmacogenomics, V3, P291, DOI 10.2165/00129785-200303050-00001
[9]   C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation [J].
Goto, M ;
Masuda, S ;
Saito, H ;
Uemoto, S ;
Kiuchi, T ;
Tanaka, K ;
Inui, K .
PHARMACOGENETICS, 2002, 12 (06) :451-457
[10]   Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation [J].
Hashida, T ;
Masuda, S ;
Uemoto, S ;
Saito, H ;
Tanaka, K ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :308-316